AZA plus R-GemOx for older adults with untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two chemotherapy drugs (R-GemOx) plus an additional drug called azacitidine (AZA) for older adults (60+) with DLBCL that hasn't been treated yet. The goal is to see if adding AZA improves the effectiveness of the standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- You have not had any chemotherapy or radiation for this lymphoma before.
- You have at least one tumor that can be measured on a scan or physical exam.
- Your doctor expects you to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
This trial tests a new combination of three drugs (EZH2 inhibitor, glofitamab, and gemcitabine/oxaliplatin) for patients with diffuse large B-cell lymphoma that has stopped responding to or come back after prior treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.